Prothena un­veils healthy vol­un­teer safe­ty da­ta for Alzheimer's drug in Bris­tol My­ers col­lab

A Big Phar­ma-part­nered Alzheimer’s can­di­date is peel­ing back its first tranch­es of da­ta.

Pro­tein dys­reg­u­la­tion out­fit Prothena an­nounced ini­tial safe­ty and tol­er­a­bil­i­ty da­ta Tues­day af­ter­noon from a Phase I tri­al for a sin­gle dose of an­ti­body can­di­date PRX005. In short, the biotech said that it con­firms the can­di­date is well-tol­er­at­ed in hu­mans and cross­es the blood-brain bar­ri­er “with ro­bust CNS pen­e­tra­tion,” ac­cord­ing to a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER